Novo Nordisk posted solid quarterly results Wednesday before the market open.The drug maker’s sales came in at 71.3 billion Danish crowns ($10.3 billion) and diluted earnings per share (EPS) of DKK 6.

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.

While plenty of people rave about the weight loss results you can get from drugs like Ozempic, there’s also been a ton of chatter over the fact that these meds are really expensive. These drugs have also been in and out of shortage, making it tough to get your hands on Ozempic and similar medications—if you can afford it.

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.